A test to predict risk of breast cancer recurrence
Detailed Product Description MammaPrint analyzes the 70 most important genes associated with breast cancer recurrence to classify each breast cancer patient into “Low Risk” or “High Risk” of developing metastases within the first 10 years after diagnosis—without the ambiguity associated with “intermediate” scores found in some other tests.
The clarity that MammaPrint delivers helps patients and physicians make informed, confident treatment management decisions.
MammaPrint is FDA-cleared (US) for women of all ages. The device is also CE marked allowing for use in the European Union.
The test is validated by peer-reviewed data and supported by the highest level of clinical evidence from a landmark randomized, prospective, phase clinical trial known as MINDACT